Does Electronic Monitoring Influence Adherence to Medication? Randomized Controlled Trial of Measurement Reactivity

• Published in: Annals of behavioral medicine 2014-12, Vol.48 (3), p.293-299
• Main Authors: Sutton, Stephen, Kinmonth, Ann-Louise, Hardeman, Wendy, Hughes, Dyfrig, Boase, Sue, Prevost, A. Toby, Kellar, Ian, Graffy, Jonathan, Griffin, Simon, Farmer, Andrew
• Format: Article
• Language: English
• Subjects: Aged; Clinical trials; Compliance; Diabetes; Diabetes Mellitus, Type 2 - drug therapy; Drug Packaging - instrumentation; Drug Packaging - standards; Drug therapy; Electrical Equipment and Supplies - standards; Family Medicine; Female; General Practice; Glycated Hemoglobin A - analysis; Health Psychology; Humans; Hypoglycemic Agents - administration & dosage; Male; Medication Adherence; Medicine; Medicine & Public Health; Middle Aged; Original; Original Article
• ISSN: 0883-6612; 1532-4796
• DOI: 10.1007/s12160-014-9595-x

Background Electronic monitoring is recommended for accurate measurement of medication adherence but a possible limitation is that it may influence adherence. Purpose To test the reactive effect of electronic monitoring in a randomized controlled trial. Methods A total of 226 adults with type 2 diabetes and HbA1c ≥58 mmol/mol were randomized to receiving their main oral glucose lowering medication in electronic containers or standard packaging. The primary outcomes were self-reported adherence measured with the MARS (Medication Adherence Report Scale; range 5–25) and HbA 1c at 8 weeks. Results Non-significantly higher adherence and lower HbA 1c were observed in the electronic container group (differences in means, adjusting for baseline value: MARS, 0.4 [95 % CI −0.1 to 0.8, p  = 0.11]; HbA 1c (mmol/mol), −1.02 [−2.73 to 0.71, p  = 0.25]). Conclusions Electronic containers may lead to a small increase in adherence but this potential limitation is outweighed by their advantages. Our findings support electronic monitoring as the method of choice in research on medication adherence. (Trial registration Current Controlled Trials ISRCT N30522359)